Suppr超能文献

AAV 介导的 plakophilin-2a 传递可阻止小鼠心脏心律失常性右心室心肌病的进展:支持人类基因治疗的临床前证据。

AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans.

机构信息

Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY (C.J.M.v.O., G.C., M.Z., M.D., M.C.).

Rocket Pharmaceuticals, Inc, Cranbury, NJ (B.N., C.B.S., K.M.S., V.M., E.F., D.R., P.Y., J.S., C.D.H.).

出版信息

Circ Genom Precis Med. 2024 Feb;17(1):e004305. doi: 10.1161/CIRCGEN.123.004305. Epub 2024 Jan 30.

Abstract

BACKGROUND

Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. No effective medical therapy is available to prevent or arrest the disease. We tested the hypothesis that adeno-associated virus vector-mediated delivery of the human gene to an adult mammalian heart deficient in PKP2 can arrest disease progression and significantly prolong survival.

METHODS

Experiments were performed using a PKP2-cKO (cardiac-specific, tamoxifen-activated PKP2 knockout murine model). The potential therapeutic, adeno-associated virus vector of serotype rh.74 (AAVrh.74)-PKP2a (PKP2 variant A; RP-A601) is a recombinant AAVrh.74 gene therapy viral vector encoding the human PKP2 variant A. AAVrh.74-PKP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-activated PKP2-cKO. PKP2 expression was confirmed by molecular and histopathologic analyses. Cardiac function and disease progression were monitored by survival analyses, echocardiography, and electrocardiography.

RESULTS

Consistent with prior findings, loss of PKP2 expression caused 100% mortality within 50 days after tamoxifen injection. In contrast, AAVrh.74-PKP2a-mediated PKP2a expression resulted in 100% survival for >5 months (at study termination). Echocardiographic analysis revealed that AAVrh.74-PKP2a prevented right ventricle dilation, arrested left ventricle functional decline, and mitigated arrhythmia burden. Molecular and histological analyses showed AAVrh.74-PKP2a-mediated transgene mRNA and protein expression and appropriate PKP2 localization at the cardiomyocyte intercalated disc. Importantly, the therapeutic benefit was shown in mice receiving AAVrh.74-PKP2a after disease onset.

CONCLUSIONS

These preclinical data demonstrate the potential for AAVrh.74-PKP2a (RP-A601) as a therapeutic for PKP2-related arrhythmogenic right ventricular cardiomyopathy in both early and more advanced stages of the disease.

摘要

背景

PKP2(桥粒斑蛋白 2)中的致病变异可导致致心律失常性右室心肌病,这是一种以危及生命的心律失常和进行性心肌病导致心力衰竭为特征的疾病。目前尚无有效的药物治疗方法可用于预防或阻止疾病进展。我们假设腺相关病毒载体介导的人类基因递送至 PKP2 缺陷的成年哺乳动物心脏,可以阻止疾病进展并显著延长生存时间。

方法

实验使用了 PKP2-cKO(心脏特异性,他莫昔芬激活的 PKP2 敲除鼠模型)。潜在的治疗性腺相关病毒载体血清型 rh.74(AAVrh.74)-PKP2a(PKP2 变异 A;RP-A601)是一种重组 AAVrh.74 基因治疗病毒载体,编码人类 PKP2 变异 A。AAVrh.74-PKP2a 通过单次尾静脉注射递送至成年小鼠体内,在他莫昔芬激活 PKP2-cKO 之前或之后进行。通过分子和组织病理学分析确认 PKP2 表达。通过生存分析、超声心动图和心电图监测心脏功能和疾病进展。

结果

与之前的发现一致,在他莫昔芬注射后 50 天内,PKP2 表达缺失导致 100%的死亡率。相比之下,AAVrh.74-PKP2a 介导的 PKP2a 表达导致 >5 个月的 100%存活率(在研究结束时)。超声心动图分析显示,AAVrh.74-PKP2a 可防止右心室扩张,阻止左心室功能下降,并减轻心律失常负担。分子和组织学分析显示,AAVrh.74-PKP2a 介导的转基因 mRNA 和蛋白表达以及适当的 PKP2 在心肌闰盘处的定位。重要的是,在疾病发作后接受 AAVrh.74-PKP2a 治疗的小鼠中显示出了治疗益处。

结论

这些临床前数据表明,AAVrh.74-PKP2a(RP-A601)具有治疗 PKP2 相关致心律失常性右室心肌病的潜力,无论是在疾病的早期还是更晚期阶段都有治疗作用。

相似文献

3
Exercise Causes Arrhythmogenic Remodeling of Intracellular Calcium Dynamics in Plakophilin-2-Deficient Hearts.
Circulation. 2022 May 10;145(19):1480-1496. doi: 10.1161/CIRCULATIONAHA.121.057757. Epub 2022 May 1.
4
Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency.
Cardiovasc Res. 2012 Sep 1;95(4):460-8. doi: 10.1093/cvr/cvs218. Epub 2012 Jul 3.
6
Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics.
Nat Cardiovasc Res. 2023 Dec;2(12):1246-1261. doi: 10.1038/s44161-023-00370-3. Epub 2023 Dec 7.
8
Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
J Am Coll Cardiol. 2006 Oct 3;48(7):1416-24. doi: 10.1016/j.jacc.2006.06.045. Epub 2006 Sep 12.
9

引用本文的文献

1
Arrhythmogenic Right Ventricular Cardiomyopathy Presenting as Monomorphic Ventricular Tachycardia.
JACC Case Rep. 2025 Aug 27;30(25):104941. doi: 10.1016/j.jaccas.2025.104941.
2
Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.
Med Sci (Basel). 2025 Jul 30;13(3):102. doi: 10.3390/medsci13030102.
3
Current and future precision therapy approaches in the long QT syndrome.
Med Genet. 2025 Jul 17;37(3):189-196. doi: 10.1515/medgen-2025-2015. eCollection 2025 Jul.
7
Current clinical applications of AAV-mediated gene therapy.
Mol Ther. 2025 Jun 4;33(6):2479-2516. doi: 10.1016/j.ymthe.2025.04.045. Epub 2025 May 5.
9
Gene therapy then and now: A look back at changes in the field over the past 25 years.
Mol Ther. 2025 May 7;33(5):1889-1902. doi: 10.1016/j.ymthe.2025.02.040. Epub 2025 Feb 28.
10
Targeting Ventricular Arrhythmias in Non-Ischemic Patients: Advances in Diagnosis and Treatment.
Diagnostics (Basel). 2025 Feb 9;15(4):420. doi: 10.3390/diagnostics15040420.

本文引用的文献

1
Desmoplakin Cardiomyopathy: Comprehensive Review of an Increasingly Recognized Entity.
J Clin Med. 2023 Apr 3;12(7):2660. doi: 10.3390/jcm12072660.
2
Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy.
Sci Transl Med. 2023 Mar 22;15(688):eadd4248. doi: 10.1126/scitranslmed.add4248.
3
The intercalated disc: a unique organelle for electromechanical synchrony in cardiomyocytes.
Physiol Rev. 2023 Jul 1;103(3):2271-2319. doi: 10.1152/physrev.00021.2022. Epub 2023 Feb 2.
4
Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy.
Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221149781. doi: 10.1177/17562864221149781. eCollection 2023.
5
Longitudinal Prediction of Ventricular Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.
Circ Arrhythm Electrophysiol. 2022 Nov;15(11):e011207. doi: 10.1161/CIRCEP.122.011207. Epub 2022 Oct 31.
6
Suppression and Replacement Gene Therapy for -Mediated Arrhythmias.
Circ Genom Precis Med. 2022 Dec;15(6):e003719. doi: 10.1161/CIRCGEN.122.003719. Epub 2022 Oct 11.
9
Exercise Causes Arrhythmogenic Remodeling of Intracellular Calcium Dynamics in Plakophilin-2-Deficient Hearts.
Circulation. 2022 May 10;145(19):1480-1496. doi: 10.1161/CIRCULATIONAHA.121.057757. Epub 2022 May 1.
10
Arrhythmogenic Right Ventricular Cardiomyopathy.
JACC Clin Electrophysiol. 2022 Apr;8(4):533-553. doi: 10.1016/j.jacep.2021.12.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验